Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer.
Accumulating data suggest that bone-seeking radiopharmaceuticals can be used to treat prostate cancer bone metastasis and improve the clinical outcome of patients with advanced prostate cancer. It remains to be elucidated whether radiopharmaceuticals enhance the disruption of the onco-niche or the eradication of micrometastatic cells in the bone marrow. The purpose of this review is to investigate the role of bone-targeted radioisotope therapy in the setting of multimodality therapy for advanced prostate cancer. We examine available data and evaluate whether dose escalation, newer generations, or repeated dosing of radiopharmaceuticals enhance their antitumor effects and whether their combination with hormone ablative therapy, chemotherapy, or novel targeted therapy can improve clinical efficacy.
Tu
Shi-Ming
SM
Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. stu@mdanderson.org
Lin
Sue-Hwa
SH
Podoloff
Donald A
DA
Logothetis
Christopher J
CJ
D000726:Androgen Antagonists / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D010006:Osteoblasts / Q000378:metabolism / Q000528:radiation effects; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000378:metabolism / Q000627:therapeutic use*
D000726:Androgen Antagonists; D011838:Radiation-Sensitizing Agents; D019275:Radiopharmaceuticals